Navigation Links
PDL BioPharma to Present at Upcoming Conferences
Date:5/8/2012

INCLINE VILLAGE, Nev., May 8, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the following upcoming conferences:

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Eleventh Annual JMP Securities Research Conference
Tuesday, May 15, 2012
9:00 a.m. PDT
San Francisco, CA

Goldman Sachs 33rd Annual Global Healthcare Conference
Thursday, June 7, 2012
8:00 a.m. PDT
Rancho Palos Verdes, CA

These presentations will be available to interested parties through live and archived audio webcasts. To access the live and subsequently archived webcasts of the presentation, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the events to allow for any software download that may be necessary. The archived webcasts will be available for seven days following each presentation.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Ondine Biopharma Announces Second Quarter 2008 Financial Results
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Therapure Biopharma Inc. opens for business with first client contracts
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. China Biopharma Effects 1 for 100 Reverse Stock Split
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... , , Catalog Number, Pack ... 100 g, , , , , , ... German , version - 42 K , ... Material Safety , Data Sheets, , MSDS , ...
... , , , , , , , ... , 1691104, Set, ... Package , Inserts/Product Instructions , , English , ... - 24 K , , US Material Safety , Data Sheets , ...
... , Here are some troubleshooting hints that we have gathered , regarding misincorporation or low fidelity of PCR ... , , , , ... , , <a , ... , , , ...
Cached Biology Technology:Trouble-shooting: Misincorporation or low fidelity 2Trouble-shooting: Misincorporation or low fidelity 3
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... 17, 2014The development of stem cell therapies to cure ... characterize stem cell populations based on cell surface markers. ... new marker that is highly expressed in a type ... which they describe in an article in BioResearch ... Liebert, Inc., publishers. The article is available free on ...
(Date:4/17/2014)... Marc Andr Gauthier and Professor Luca Razzari of ... been awarded large grants from the John R. ... Innovation (CFI) for the acquisition of state-of-the-art biotech ... added matching grants from the Ministre de l,Enseignement ... de la Technologie (MESRST). These new laboratories will ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2New state-of-the-art biotech and nanotech equipment for INRS 2
... the body, a virus such as HIV invades body cells ... Once inside the cell, the invading microbe's genetic material takes ... more copies of the virus, which then spill out to ... that once a virus begins fusing with a cell's membrane, ...
... in prospect with a clinical drug trial to begin in ... would open the way to relief in the 10% of ... over 500,000,000 people. , The Walter and Eliza Hall ... Guinea Institute of Medical Research (PNGIMR) and the University of ...
... Medical Center (SFVAMC) and the University of California, San ... bronchitis, which is thought to lead to obliterative bronchitis ... transplanted lungs. , The researchers hope their results will ... standard test for chronic lung rejection, as well as ...
Cached Biology News:Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3Old drug, new tricks: Prospects for slashing the impact of malaria 2Researchers identify genes associated with lung transplant rejection 2
... Labsystems Nepheloskan Ascent is the ... measurement in microplates. Nepheloskan measures ... ultra-sensitive technique for particle quantification. ... solubility testing in drug discovery, ...
... Crotalus adamanteus venom Description: Phosphodiesterase ... used in studying nucleic acid ... It hydrolyzes 5'-mononucleotides from 3'-hydroxy-terminated ... Phosphodiesterase I cleaves ADP-ribosylated proteins ...
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... Useful for the determination of digitonin and digoxin. ... EDTA Na 4 and 0.06% NaCl Preparation ... al., Biochem. Biophys. Res. Commun., 19, 755 ... mole of inorganic phosphorus from ATP per min ...
Biology Products: